These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17276980)

  • 1. Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor.
    Gorlatova NV; Cale JM; Elokdah H; Li D; Fan K; Warnock M; Crandall DL; Lawrence DA
    J Biol Chem; 2007 Mar; 282(12):9288-96. PubMed ID: 17276980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis.
    Leik CE; Su EJ; Nambi P; Crandall DL; Lawrence DA
    J Thromb Haemost; 2006 Dec; 4(12):2710-5. PubMed ID: 17010152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1).
    van Meijer M; Gebbink RK; Preissner KT; Pannekoek H
    FEBS Lett; 1994 Oct; 352(3):342-6. PubMed ID: 7523190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain.
    Schar CR; Jensen JK; Christensen A; Blouse GE; Andreasen PA; Peterson CB
    J Biol Chem; 2008 Oct; 283(42):28487-96. PubMed ID: 18658131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements.
    Blouse GE; Dupont DM; Schar CR; Jensen JK; Minor KH; Anagli JY; Gårdsvoll H; Ploug M; Peterson CB; Andreasen PA
    Biochemistry; 2009 Mar; 48(8):1723-35. PubMed ID: 19193026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitor properties concomitant with an allosteric up-regulation of its antiadhesive properties.
    Ngo TH; Hoylaerts MF; Knockaert I; Brouwers E; Declerck PJ
    J Biol Chem; 2001 Jul; 276(28):26243-8. PubMed ID: 11342530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
    Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
    Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases.
    Komissarov AA; Andreasen PA; Bødker JS; Declerck PJ; Anagli JY; Shore JD
    J Biol Chem; 2005 Jan; 280(2):1482-9. PubMed ID: 15516335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights into the size and stoichiometry of the plasminogen activator inhibitor type-1.vitronectin complex.
    Podor TJ; Shaughnessy SG; Blackburn MN; Peterson CB
    J Biol Chem; 2000 Aug; 275(33):25402-10. PubMed ID: 10821827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface.
    Podor TJ; Singh D; Chindemi P; Foulon DM; McKelvie R; Weitz JI; Austin R; Boudreau G; Davies R
    J Biol Chem; 2002 Mar; 277(9):7529-39. PubMed ID: 11744725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood.
    Rupin A; Gaertner R; Mennecier P; Richard I; Benoist A; De Nanteuil G; Verbeuren TJ
    Thromb Res; 2008; 122(2):265-70. PubMed ID: 18177924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Localization of vitronectin binding domain in plasminogen activator inhibitor-1.
    Lawrence DA; Berkenpas MB; Palaniappan S; Ginsburg D
    J Biol Chem; 1994 May; 269(21):15223-8. PubMed ID: 7515053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localization of a vitronectin binding region of plasminogen activator inhibitor-1.
    Padmanabhan J; Sane DC
    Thromb Haemost; 1995 May; 73(5):829-34. PubMed ID: 7482411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1.
    Li SH; Reinke AA; Sanders KL; Emal CD; Whisstock JC; Stuckey JA; Lawrence DA
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):E4941-9. PubMed ID: 24297881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional effects of single amino acid substitutions in the region of Phe113 to Asp138 in the plasminogen activator inhibitor 1 molecule.
    Sui GC; Wiman B
    Biochem J; 1998 Apr; 331 ( Pt 2)(Pt 2):409-15. PubMed ID: 9531478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The vitronectin binding area of plasminogen activator inhibitor-1, mapped by mutagenesis and protection against an inactivating organochemical ligand.
    Jensen JK; Wind T; Andreasen PA
    FEBS Lett; 2002 Jun; 521(1-3):91-4. PubMed ID: 12067733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides.
    Germer M; Kanse SM; Kirkegaard T; Kjøller L; Felding-Habermann B; Goodman S; Preissner KT
    Eur J Biochem; 1998 May; 253(3):669-74. PubMed ID: 9654064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A method for defining binding sites involved in protein-protein interactions: analysis of the binding of plasminogen activator inhibitor 1 to the somatomedin domain of vitronectin.
    Royle G; Deng G; Seiffert D; Loskutoff DJ
    Anal Biochem; 2001 Sep; 296(2):245-53. PubMed ID: 11554720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state.
    Mathiasen L; Dupont DM; Christensen A; Blouse GE; Jensen JK; Gils A; Declerck PJ; Wind T; Andreasen PA
    Mol Pharmacol; 2008 Sep; 74(3):641-53. PubMed ID: 18559377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.